Oculis Completes Randomization of 176 Patients in Dry Eye Trial
Oculis completed randomization in its PREDICT-1 registrational trial of licaminlimab for TNFR1-mediated dry eye disease. Topline data are expected around year-end 2026.
Oculis completed randomization in its PREDICT-1 registrational trial of licaminlimab for TNFR1-mediated dry eye disease. Topline data are expected around year-end 2026.